Predicting survival in head and neck cancer: External validation and update of the prognostic model OncologIQ in 2189 patients

Arta Hoesseini; Nikki van Leeuwen; Marinella P.J. Offerman; Jang Zhang; Emilie A.C. Dronkers; Aniel Sewnaik; Hester F. Lingsma; Robert Jan Baatenburg de Jong

doi:10.1002/hed.26716

Predicting survival in head and neck cancer: External validation and update of the prognostic model OncologIQ in 2189 patients

Arta Hoesseini^*, Nikki van Leeuwen, Marinella P.J. Offerman, Jang Zhang, Emilie A.C. Dronkers, Aniel Sewnaik, Hester F. Lingsma, Robert Jan Baatenburg de Jong

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

10 Citations (Scopus)

Abstract

Background: Disclosing prognostic information is necessary to enable patients to make well-informed treatment decisions. OncologIQ is a prognostic model that predicts the overall survival (OS) probability in patients with head and neck squamous cell carcinoma (HNSCC). We aimed to externally validate and update the model with new prognostic factors and translate it to a clinically useful tool. Methods: A consecutive retrospective sample of 2189 patients eligible for curative treatment of a primary HNSCC were selected. Discriminative performance was determined using the C-statistic. Results: External validation showed systematic underestimation of OS in the new population, and reasonable discrimination (C-statistic 0.67). Adding smoking, pack years, BMI, weight loss, WHO performance, socioeconomic status, and p16 positivity to the recalibrated multivariable model, improved the internally validated C-statistic to 0.71. The model showed minor optimism and was translated in an online tool (www.oncologiq.nl). Conclusions: The updated model enables personalized patient counseling during treatment decision consultations.

Original language	English
Pages (from-to)	2445-2456
Number of pages	12
Journal	Head and Neck
Volume	43
Issue number	8
DOIs	https://doi.org/10.1002/hed.26716
Publication status	Published - 7 May 2021

Bibliographical note

Funding Information:
We would like to thank all the medical students that joined the RONCDOC research team. We also would like to thank L. M. Lawant, E. F. van der Poel, and T. Grevelink for enabling the visual formats of OncologIQ. This research partly received funding from the National Health Care Institute (Zorginstituut Nederland).

Funding Information:
We would like to thank all the medical students that joined the RONCDOC research team. We also would like to thank L. M. Lawant, E. F. van der Poel, and T. Grevelink for enabling the visual formats of OncologIQ. This research partly received funding from the National Health Care Institute (Zorginstituut Nederland).

Publisher Copyright:
© 2021 The Authors. Head & Neck published by Wiley Periodicals LLC.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/hed.26716

Cite this

@article{7b27ab89e4184849bbe4c8cda222b023,

title = "Predicting survival in head and neck cancer: External validation and update of the prognostic model OncologIQ in 2189 patients",

abstract = "Background: Disclosing prognostic information is necessary to enable patients to make well-informed treatment decisions. OncologIQ is a prognostic model that predicts the overall survival (OS) probability in patients with head and neck squamous cell carcinoma (HNSCC). We aimed to externally validate and update the model with new prognostic factors and translate it to a clinically useful tool. Methods: A consecutive retrospective sample of 2189 patients eligible for curative treatment of a primary HNSCC were selected. Discriminative performance was determined using the C-statistic. Results: External validation showed systematic underestimation of OS in the new population, and reasonable discrimination (C-statistic 0.67). Adding smoking, pack years, BMI, weight loss, WHO performance, socioeconomic status, and p16 positivity to the recalibrated multivariable model, improved the internally validated C-statistic to 0.71. The model showed minor optimism and was translated in an online tool (www.oncologiq.nl). Conclusions: The updated model enables personalized patient counseling during treatment decision consultations.",

author = "Arta Hoesseini and {van Leeuwen}, Nikki and Offerman, {Marinella P.J.} and Jang Zhang and Dronkers, {Emilie A.C.} and Aniel Sewnaik and Lingsma, {Hester F.} and {Baatenburg de Jong}, {Robert Jan}",

note = "Funding Information: We would like to thank all the medical students that joined the RONCDOC research team. We also would like to thank L. M. Lawant, E. F. van der Poel, and T. Grevelink for enabling the visual formats of OncologIQ. This research partly received funding from the National Health Care Institute (Zorginstituut Nederland). Funding Information: We would like to thank all the medical students that joined the RONCDOC research team. We also would like to thank L. M. Lawant, E. F. van der Poel, and T. Grevelink for enabling the visual formats of OncologIQ. This research partly received funding from the National Health Care Institute (Zorginstituut Nederland). Publisher Copyright: {\textcopyright} 2021 The Authors. Head & Neck published by Wiley Periodicals LLC.",

year = "2021",

month = may,

day = "7",

doi = "10.1002/hed.26716",

language = "English",

volume = "43",

pages = "2445--2456",

journal = "Head and Neck",

issn = "1043-3074",

publisher = "John Wiley & Sons Inc.",

number = "8",

}

TY - JOUR

T1 - Predicting survival in head and neck cancer

T2 - External validation and update of the prognostic model OncologIQ in 2189 patients

AU - Hoesseini, Arta

AU - van Leeuwen, Nikki

AU - Offerman, Marinella P.J.

AU - Zhang, Jang

AU - Dronkers, Emilie A.C.

AU - Sewnaik, Aniel

AU - Lingsma, Hester F.

AU - Baatenburg de Jong, Robert Jan

N1 - Funding Information: We would like to thank all the medical students that joined the RONCDOC research team. We also would like to thank L. M. Lawant, E. F. van der Poel, and T. Grevelink for enabling the visual formats of OncologIQ. This research partly received funding from the National Health Care Institute (Zorginstituut Nederland). Funding Information: We would like to thank all the medical students that joined the RONCDOC research team. We also would like to thank L. M. Lawant, E. F. van der Poel, and T. Grevelink for enabling the visual formats of OncologIQ. This research partly received funding from the National Health Care Institute (Zorginstituut Nederland). Publisher Copyright: © 2021 The Authors. Head & Neck published by Wiley Periodicals LLC.

PY - 2021/5/7

Y1 - 2021/5/7

N2 - Background: Disclosing prognostic information is necessary to enable patients to make well-informed treatment decisions. OncologIQ is a prognostic model that predicts the overall survival (OS) probability in patients with head and neck squamous cell carcinoma (HNSCC). We aimed to externally validate and update the model with new prognostic factors and translate it to a clinically useful tool. Methods: A consecutive retrospective sample of 2189 patients eligible for curative treatment of a primary HNSCC were selected. Discriminative performance was determined using the C-statistic. Results: External validation showed systematic underestimation of OS in the new population, and reasonable discrimination (C-statistic 0.67). Adding smoking, pack years, BMI, weight loss, WHO performance, socioeconomic status, and p16 positivity to the recalibrated multivariable model, improved the internally validated C-statistic to 0.71. The model showed minor optimism and was translated in an online tool (www.oncologiq.nl). Conclusions: The updated model enables personalized patient counseling during treatment decision consultations.

AB - Background: Disclosing prognostic information is necessary to enable patients to make well-informed treatment decisions. OncologIQ is a prognostic model that predicts the overall survival (OS) probability in patients with head and neck squamous cell carcinoma (HNSCC). We aimed to externally validate and update the model with new prognostic factors and translate it to a clinically useful tool. Methods: A consecutive retrospective sample of 2189 patients eligible for curative treatment of a primary HNSCC were selected. Discriminative performance was determined using the C-statistic. Results: External validation showed systematic underestimation of OS in the new population, and reasonable discrimination (C-statistic 0.67). Adding smoking, pack years, BMI, weight loss, WHO performance, socioeconomic status, and p16 positivity to the recalibrated multivariable model, improved the internally validated C-statistic to 0.71. The model showed minor optimism and was translated in an online tool (www.oncologiq.nl). Conclusions: The updated model enables personalized patient counseling during treatment decision consultations.

UR - http://www.scopus.com/inward/record.url?scp=85105134100&partnerID=8YFLogxK

U2 - 10.1002/hed.26716

DO - 10.1002/hed.26716

M3 - Article

C2 - 33960553

AN - SCOPUS:85105134100

SN - 1043-3074

VL - 43

SP - 2445

EP - 2456

JO - Head and Neck

JF - Head and Neck

IS - 8

ER -

Predicting survival in head and neck cancer: External validation and update of the prognostic model OncologIQ in 2189 patients

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this